AC Immune (ACIU) Liabilities and Shareholders Equity (2015 - 2026)

AC Immune (ACIU) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $175.5 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 74646.66% year-over-year to $175.5 billion in Q1 2026; TTM through Mar 2026 was $176.1 billion, a 16787.22% increase from a year earlier, with the FY2025 full-year figure at $186.0 million, down 29.42% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $175.5 billion, up from $193.0 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ACIU reached as high as $175.5 billion in Q1 2026 and fell as low as $225087.4 in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $10.5 billion across 5 years, with a median of $206.1 million in 2023.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 95982.08% in 2022 and fell as far as 31.93% in 2022.
• Year by year, Liabilities and Shareholders Equity stood at $193.0 million in 2022, then climbed by 6.78% to $206.1 million in 2023, then advanced by 27.9% to $263.6 million in 2024, then retreated by 26.78% to $193.0 million in 2025, then soared by 90828.78% to $175.5 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $175.5 billion in Q1 2026, $193.0 million in Q4 2025, and $214.5 million in Q3 2025.